Overall, our in vitro data suggested that the sequence-specific LMP1-shRNA2 not only interferes with the oncogenic action of LMP1 gene in NPC but also provokes anti-tumor immunity. The gene discussed is PDLIM7; the disease is nasopharyngeal carcinoma.